Recipients of VIP-R antagonist peptide/anti-PD-1 combination therapy had increased homing, activation and proliferation of intra-tumoral CD4+ and CD8+ T cells and marked increases in tumor-antigen-specific T cells within the TME. Here, CD8A is linked to neoplasm.